19th Apr 2021 17:25
19 April 2021
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Roger McDowell, a Director of the Company, that on 16 April 2021 he purchased 900,000 Ordinary Shares in the Company at a price of 5.00p per share. Roger McDowell now holds 3,400,000 Ordinary Shares in the Company, which represents approximately 1.15% of the issued share capital of the Company.
The below notification is made in accordance with the requirements of the UK Market Abuse Regulation.
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Roger McDowell | ||||
| Reason for the notification | |||||
a) | Position/status: | Non-Executive Director | ||||
b) | Initial notification/Amendment: | Initial Notification | ||||
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Proteome Sciences Plc | ||||
b) | LEI: | 213800Q62ICXANKU2986 | ||||
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 1p nominal value GB0003104196 | ||||
b) | Nature of the transaction: | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s): |
| ||||
d) | Aggregated information: · Aggregated volume: · Price: | Single transaction as in 4 c) above
| ||||
e) | Date of the transaction: | 16 April 2021 | ||||
f) | Place of the transaction: | London Stock Exchange, AIM (XLON) | ||||
For further information please contact:
Proteome Sciences plc | |
Mariola Soehngen M.D., Chief Executive Officer Dr Ian Pike, Chief Scientific Officer
| Tel: +44 (0)20 7043 2116 |
Allenby Capital Limited (AIM Nominated Adviser & Broker) | |
John Depasquale / Jeremy Porter - Corporate Finance Tony Quirke - Sales and Corporate Broking | Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.
Related Shares:
Proteome